Sean Tunis, MD, MSc
Sean Tunis is director of the Center for Medical Technology Policy and a principal at Rubix Health. He is the former chief medical officer and director of the Office of...
Oncology biomarkers have the potential to significantly improve the quality and efficiency of health care, but their value hinges on whether payers will support the science. Private payer adoption of CMS' "coverage with evidence development" decisions could provide the appropriate regulatory and reimbursement framework.
Sean Tunis, MD, MSc
Sean Tunis is director of the Center for Medical Technology Policy and a principal at Rubix Health. He is the former chief medical officer and director of the Office of...